News Image

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Provided By GlobeNewswire

Last update: Mar 31, 2025

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights.

Read more at globenewswire.com

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (7/25/2025, 8:04:02 PM)

After market: 0.6301 -0.1 (-13.68%)

0.73

-0.04 (-5.43%)



Find more stocks in the Stock Screener

CLDI Latest News and Analysis

Follow ChartMill for more